top of page
Metastasis Publications
Highlighting 2023/2024's metastasis publications
EGFR and PI3K Signalling Pathways as Promising Targets on Circulating Tumour Cells from Patients with Metastatic Gastric Adenocarcinoma.
Piper AK, Penney C, Holliday J, Tincknell G, Ma Y, Napaki S, Pantel K, Brungs D, Ranson M.
Int J Mol Sci. 2024 May 20;25(10):5565. doi: 10.3390/ijms25105565.
PMID: 38791602; PMCID: PMC11122469.
B7-H3 Expression in Breast Cancer and Brain Metastasis.
Joshi V, Beecher K, Lim M, Stacey A, Feng Y, Jat PS, Duijf PHG, Simpson PT, Lakhani SR, McCart Reed AE
Int J Mol Sci. 2024 Apr 3;25(7):3976. doi: 10.3390/ijms25073976.
PMID: 38612786; PMCID: PMC11012592.
Tumor Biomechanics Alters Metastatic Dissemination of Triple Negative Breast Cancer via Rewiring Fatty Acid Metabolism.
Filipe EC, Velayuthar S, Philp A, Nobis M, Latham SL, Parker AL, Murphy KJ, Wyllie K, Major GS, Contreras O, Mok ETY, Enriquez RF, McGowan S, Feher K, Quek LE, Hancock SE, Yam M, Tran E, Setargew YFI, Skhinas JN, Chitty JL, Phimmachanh M, Han JZR, Cadell AL, Papanicolaou M, Mahmodi H, Kiedik B, Junankar S, Ross SE, Lam N, Coulson R, Yang J, Zaratzian A, Da Silva AM, Tayao M, Chin IL, Cazet A, Kansara M, Segara D, Parker A, Hoy AJ, Harvey RP, Bogdanovic O, Timpson P, Croucher DR, Lim E, Swarbrick A, Holst J, Turner N, Choi YS, Kabakova IV, Philp A, Cox TR.
Adv Sci (Weinh). 2024 Apr 11:e2307963. doi: 10.1002/advs.202307963.
Epub ahead of print. PMID: 38602451.
Plasminogen activator inhibitor 1 is associated with high-grade serous ovarian cancer metastasis and is reduced in patients who have received neoadjuvant chemotherapy.
Kelly TE, Spillane CL, Ward MP, Hokamp K, Huang Y, Tewari P, Martin CM, Norris LA, Mohamed BM, Bates M, Brooks R, Selemidis S, Brooks DA, Kamran W, Saadeh FA, O'Toole SA, O'Leary JJ.
Front Cell Dev Biol. 2023 Dec 7;11:1150991. doi: 10.3389/fcell.2023.1150991.
PMID: 38143926; PMCID: PMC10740207.
Suppression of TNBC metastasis by doxazosin, a novel dual inhibitor of c-MET/EGFR.
Kim S, Park JM, Park S, Jung E, Ko D, Park M, Seo J, Nam KD, Kang YK, Lee K, Farrand L, Kim YJ, Kim JY, Seo JH.
J Exp Clin Cancer Res. 2023 Nov 4;42(1):292. doi: 10.1186/s13046-023-02866-z.
PMID: 37924112; PMCID: PMC10625208.
Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial.
Hofman MS, Emmett L, Sandhu S, Iravani A, Buteau JP, Joshua AM, Goh JC, Pattison DA, Tan TH, Kirkwood ID, Ng S, Francis RJ, Gedye C, Rutherford NK, Weickhardt A, Scott AM, Lee ST, Kwan EM, Azad AA, Ramdave S, Redfern AD, Macdonald W, Guminski A, Hsiao E, Chua W, Lin P, Zhang AY, Stockler MR, Williams SG, Martin AJ, Davis ID; TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group.
Lancet Oncol. 2024 Jan;25(1):99-107. doi: 10.1016/S1470-2045(23)00529-6.
Epub 2023 Nov 30. PMID: 38043558.
Sex as a Predictor of Response to Immunotherapy in Advanced Cutaneous Squamous Cell Carcinoma.
Yeo N, Genenger B, Aghmesheh M, Thind A, Napaki S, Perry J, Ashford B, Ranson M, Brungs D.
Cancers (Basel). 2023 Oct 17;15(20):5026. doi: 10.3390/cancers15205026.
PMID: 37894393; PMCID: PMC10605413.
EYA4 promotes breast cancer progression and metastasis through its role in replication stress avoidance.
de la Peña Avalos B, Tropée R, Duijf PHG, Dray E.
Mol Cancer. 2023 Sep 30;22(1):158. doi: 10.1186/s12943-023-01861-4.
PMID: 37777742; PMCID: PMC10543271.
Single-cell RNA sequencing captures patient-level heterogeneity and associated molecular phenotypes in breast cancer pleural effusions.
Whitfield HJ, Berthelet J, Mangiola S, Bell C, Anderson RL, Pal B, Yeo B, Papenfuss AT, Merino D, Davis MJ.
Clin Transl Med. 2023 Sep;13(9):e1356. doi: 10.1002/ctm2.1356.
PMID: 37691350; PMCID: PMC10493486.
Experimental and spontaneous metastasis assays can result in divergence in clonal architecture.
Serrano A, Weber T, Berthelet J, El-Saafin F, Gadipally S, Charafe-Jauffret E, Ginestier C, Mariadason JM, Oakes SR, Britt K, Naik SH, Merino D.
Commun Biol. 2023 Aug 7;6(1):821. doi: 10.1038/s42003-023-05167-5.
PMID: 37550477; PMCID: PMC10406815.
Targeted Single-cell Isolation of Spontaneously Escaping Live Melanoma Cells for Comparative Transcriptomics.
Tearle JLE, Arjunan SNV, Tay SS, Colakoglu F, Cremasco J, Golo M, Biro M.
Cancer Res Commun. 2023 Aug 11;3(8):1524-1537. doi: 10.1158/2767-9764.CRC-22-0305.
PMID: 37575281; PMCID: PMC10416804.​
Interferon-ε is a tumour suppressor and restricts ovarian cancer.
Marks ZRC, Campbell NK, Mangan NE, Vandenberg CJ, Gearing LJ, Matthews AY, Gould JA, Tate MD, Wray-McCann G, Ying L, Rosli S, Brockwell N, Parker BS, Lim SS, Bilandzic M, Christie EL, Stephens AN, de Geus E, Wakefield MJ, Ho GY, McNally O; Australian Ovarian Cancer Study; McNeish IA, Bowtell DDL, de Weerd NA, Scott CL, Bourke NM, Hertzog PJ.
Nature. 2023 Aug;620(7976):1063-1070. doi: 10.1038/s41586-023-06421-w.
pub 2023 Aug 16. PMID: 37587335.​
Protocol for the generation and automated confocal imaging of whole multi-cellular tumor spheroids.
Genenger B, McAlary L, Perry JR, Ashford B, Ranson M.
STAR Protoc. 2023 Jun 9;4(2):102331. doi: 10.1016/j.xpro.2023.102331.
PMID: 37300829; PMCID: PMC10276290.​
Spatial analysis with SPIAT and spaSim to characterize and simulate tissue microenvironments.
Feng Y, Yang T, Zhu J, Li M, Doyle M, Ozcoban V, Bass GT, Pizzolla A, Cain L, Weng S, Pasam A, Kocovski N, Huang YK, Keam SP, Speed TP, Neeson PJ, Pearson RB, Sandhu S, Goode DL, Trigos AS.
Nat Commun. 2023 May 15;14(1):2697. doi: 10.1038/s41467-023-37822-0.
PMID: 37188662; PMCID: PMC10185501.​
Multiomic analysis of homologous recombination-deficient end-stage high-grade serous ovarian cancer.
Burdett NL, Willis MO, Alsop K, Hunt AL, Pandey A, Hamilton PT, Abulez T, Liu X, Hoang T, Craig S, Fereday S, Hendley J, Garsed DW, Milne K, Kalaria S, Marshall A, Hood BL, Wilson KN, Conrads KA, Pishas KI, Ananda S, Scott CL, Antill Y, McNally O, Mileshkin L, Hamilton A, Au-Yeung G, Devereux L, Thorne H, Bild A, Bateman NW, Maxwell GL, Chang JT, Conrads TP, Nelson BH, Bowtell DDL, Christie EL.
Nat Genet. 2023 Mar;55(3):437-450. doi: 10.1038/s41588-023-01320-2.
Epub 2023 Feb 27. PMID: 36849657.​
Integrin avB3 Is a Master Regulator of Resistance to TKI-Induced Ferroptosis in HER2-Positive Breast Cancer.
Nagpal A, Needham K, Lane DJR, Ayton S, Redvers RP, John M, Selistre-de-Araujo HS, Denoyer D, Pouliot N.
Cancers. 2023 Feb 14; 15(4):1216. doi: 10.3390/cancers15041216.
PMID: 36831558; PMCID: PMC9954089
​
Therapeutic targeting of anoikis resistance in cutaneous melanoma metastasis.
Neuendorf HM, Simmons JL, Boyle GM.
Front Cell Dev Biol, 2023 Apr 26;11:1183328. doi: 10.3389/fcell.2023.1183328. Epub 2023 Apr 26.
PMID: 37181747; PMCID: PMC10169659.
Examining the efficacy of localised gemcitabine therapy for the treatment of pancreatic cancer using a hybrid agent-based model.
Jenner AL, Kelly W, Dallaston M, Araujo R, Parfitt I, Steinitz D, Pooladvand P, Kim PS, Wade SJ, Vine KL.
PLoS Comput Biol. 2023 Jan 17;19(1):e1010104. doi: 10.1371/journal.pcbi.1010104.
PMID: 36649330; PMCID: PMC9891514.
bottom of page